ARTICLE | Company News
CUBRC Inc., Tetraphase infectious news
October 17, 2011 7:00 AM UTC
NIH's National Institute of Allergy and Infectious Diseases (NIAID) awarded the partners up to $36 million over five years to develop TP-271, a tetracycline antibiotic, to treat tularemia and respira...